Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
C

Captor Therapeutics SA
WSE:CTX

Watchlist Manager
Captor Therapeutics SA
WSE:CTX
Watchlist
Price: 78.8 PLN 2.87%
Market Cap: zł435.8m
Write Note Create Alert Ask AI

Captor Therapeutics SA
Investor Relations

Captor Therapeutics SA engages in the development of protein degradation drugs for cancer and autoimmune diseases. The company is headquartered in Wroclaw, Woj. Dolnoslaskie and currently employs 98 full-time employees. The company went IPO on 2021-04-19. The firm works in the field of neoplastic and autoimmune diseases for which there is no treatment option, or the available methods show therapeutic limitations. The firm covers aspects of early-stage drug development to deliver therapeutics for life-threatening and life-impairing diseases. The broadly applicable Optigrade tm Targeted Protein Degradation (TPD) platform allows for the creation of new drugs.

Show more
Loading
CTX
WIG20
1Y 3Y 5Y 10Y 15Y 20Y
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Dr. Thomas Shepherd Ph.D.
CEO & President of the Management Board
No Bio Available
Mr. Sylvain Cottens
Co-Founder & Senior VP of Chemistry
No Bio Available
Mr. Michal Walczak
Member of Management Board & Chief Scientific Officer
No Bio Available
Anna Pawluk
Vice President of Operations
No Bio Available
Ms. Marta Tomaszewska
Vice President of People & Culture
No Bio Available
Mr. Michal Bista
Head of Structure, Fragments & Biophysics
No Bio Available
Robert Dyjas
Head of Medical Affairs & Clinical Development
No Bio Available

Contacts

Address
WOJ. DOLNOSLASKIE
Wroclaw
ul. Dunska 11
Contacts
www.captortherapeutics.pl
sparklesyt

See Also

Summary
CTX intrinsic value, competitors valuation, and company profile.
DCF Valuation
CTX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
CTX stock valuation using valuation multiples.
Wall Street Estimates
CTX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
CTX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Back to Top
ALPHA SPREAD
Follow us
Join more than 314,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.